Sertraline
| 證據等級: L5 | 預測適應症: 8 個 |
目錄
Sertraline: From Depression to Paranoid Personality Disorder
One-Sentence Summary
Sertraline is a well-known selective serotonin reuptake inhibitor (SSRI), a drug class established for treating depression and multiple anxiety-related disorders. The TxGNN model predicts it may be effective for Paranoid Personality Disorder, but this specific indication is currently supported only by 4 loosely related publications and no registered clinical trials.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available — no TFDA/local license record found (drug is not marketed in this jurisdiction); sertraline is broadly known as an SSRI antidepressant |
| Predicted New Indication | Paranoid Personality Disorder |
| TxGNN Prediction Score | 99.93% |
| Evidence Level | L4 |
| Market Status | 未上市 (Not Marketed) |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available (Data Gap, severity: High). Based on general pharmacological knowledge, sertraline is a selective serotonin reuptake inhibitor (SSRI) that increases synaptic serotonin concentration by blocking presynaptic reuptake; this class of drugs is broadly used across mood and anxiety disorders.
However, the link between sertraline’s known efficacy and paranoid personality disorder is weak. Existing literature focuses mostly on borderline personality disorder or personality disorders comorbid with major depression, not on the core symptoms of paranoid PD (pervasive suspicion and distrust). No study directly examines a serotonergic mechanism specific to paranoid ideation or distrust as a treatment target.
As a result, this prediction should be regarded as an indirect, model-driven inference rather than a mechanistically grounded hypothesis. The evidence pack itself classifies this candidate as L4 (preclinical/mechanistic-level at best) with a Hold recommendation.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 9817625 | 1998 | Cohort/Comparative | International Clinical Psychopharmacology | 308 depressed patients assessed for personality disorder comorbidity; treated 24 weeks with sertraline or citalopram — general personality disorder findings, not paranoid-PD-specific |
| 18848360 | 2008 | Open-label augmentation study (borderline PD) | Psychiatry Research | Aripiprazole augmentation in 21 sertraline-resistant borderline PD outpatients; not paranoid PD |
| 36853245 | 2023 | Review (borderline PD) | JAMA | General review of borderline personality disorder epidemiology and management; does not address paranoid PD |
| 11686052 | 2001 | Review (unrelated topic) | L’Encéphale | Review of interferon-alpha-induced psychiatric disorders; not related to sertraline or paranoid PD |
Market Information
No license records are available — sertraline is currently not marketed in this jurisdiction (0 NDAs on file), so product/dosage-form details cannot be reported.
Safety Considerations
Please refer to the package insert for safety information.
(Note: Key warnings, contraindications, and drug-interaction data are flagged as a Blocking data gap — DG001 — pending TFDA label retrieval and parsing.)
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence for sertraline in paranoid personality disorder is indirect — drawn from studies on borderline PD or general PD/depression comorbidity — with no trials or mechanistic studies targeting paranoid PD’s core symptoms (suspicion, distrust). Combined with a Blocking safety data gap (no TFDA warnings/contraindications available), this candidate does not meet the bar to proceed.
To proceed, the following is needed:
- TFDA label data (warnings, contraindications) — currently Blocking (DG001)
- Confirmed mechanism of action (DG001/DG002 remediation via DrugBank API)
- Any preclinical or mechanistic study directly addressing paranoid-spectrum symptoms and serotonergic modulation
- Reassessment if new clinical trials or targeted literature emerge
Note for portfolio review: within this same evidence pack, a different predicted indication for sertraline — agoraphobia (linked to panic disorder) — has substantially stronger support (Evidence Level L1, multiple completed Phase 4 RCTs including a 321-patient double-blind trial, plus systematic reviews/meta-analyses), and is scored “Proceed with Guardrails.” If prioritizing sertraline repurposing candidates, agoraphobia/panic disorder is the far stronger near-term opportunity compared to paranoid personality disorder.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.